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Discussion Paper
A visual summary of the EUROCARE-4 results: a UK perspective
H Møller*,1, KM Linklater1 and D Robinson1
1Kings College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK
BACKGROUND: This paper provides a one-page visual summary of the previously published relative survival estimates for 42 types of
cancers in 23 countries in Europe.
METHODS: The cancer patients in these analyses were 15 years or older at the time of their diagnosis in the period 1995–1999.
Follow-up was to the end of 2003 and relative survival estimates were computed by the cohort method.
RESULTS: The analysis of 1-year survival had good discriminatory power and visibly separated a group of countries with consistently
high survival estimates (Switzerland, France, Sweden, Belgium and Italy) and another group of countries with lower estimates (Poland,
Czech Republic, Ireland, Denmark and United Kingdom–Northern Ireland). After the first year, there was less variation between the
countries.
CONCLUSION: To more fully understand the UK situation, a rational comparison would select countries with data-quality, prosperity
and healthcare systems that are similar to the United Kingdom. In otherwise comparable populations, a pronounced difference in
1-year survival is most likely to be due to variation in a strong prognostic factor, which exerts its effect in the short term. A likely
explanation for the short-term survival deficit in the United Kingdom compared with the Nordic countries is a less favourable stage
distribution in the United Kingdom. However, the present superficial analysis does not exclude possible functions for other factors
relating to the organisation and quality of cancer care services.
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Detailed results from the fourth generation of the EUROCARE
cancer survival study were published in 2009 (Sant et al, 2009),
providing information on survival from 42 different cancers in 23
European countries, and a number of journal articles relating to
specific types of cancer have been published in a special issue of
the European Journal of Cancer (EUROCARE Working Group,
2009). Apart from the specific clinical and public health interest in
prognosis and survival for particular types of cancer, the
collaborative survival study as a whole may help elucidate
Europe-wide patterns of cancer survival, and provide interpreta-
tions and explanations that would not necessarily appear from
detailed analyses of the individual diseases. Previous reports from
the study noted important variations between larger geographical
regions in Europe, increases in cancer survival with calendar time
and associations with national health expenditure (Berrino et al,
2007; Verdecchia et al, 2007).
Several years ago, Ronald Damhuis from the cancer registry in
Rotterdam suggested (personal communication, 2002) that varia-
tions in cancer survival between European countries might be
more important in the short term (i.e. in the first year) after the
cancer diagnosis, rather than in the longer term as measured by
the then conventional 5- or 10-year cumulative survival estimates.
This idea was substantiated by a detailed analysis of colorectal
cancer survival in North West Europe (Engholm et al, 2007), and
the routine reporting of the EUROCARE-4 study now includes
survival estimates for the first year of follow-up (1-year survival) as
well as an estimate for survival in the subsequent 4-year period, the
latter called the 5-year survival conditional on surviving the first
year (here abbreviated ‘5|1-year conditional survival’).
This paper provides a one-page visual summary of 1-year
survival and 5|1-year conditional survival for 42 types of cancers in
23 countries in Europe.
MATERIALS AND METHODS
We extracted the 1-year and 5|1-year conditional survival
estimates from the main EUROCARE-4 summary article (Sant
et al, 2009). Both sets of results are estimates of relative survival,
expressing probabilities of survival that have been corrected for
the general, all-cause mortality in each population. Likewise, the
estimates are age standardised to facilitate comparisons between
countries with different age distributions (Corazziari et al, 2004).
The cancer patients in these analyses were 15 years or older at the
time of their diagnosis in the period 1995–1999. Follow-up was to
the end of 2003 and relative survival estimates were computed by
the cohort method (Brenner and Hakulinen, 2009).
For each survival period, we identified the upper and lower
quintiles of the distribution of survival estimates and colour coded
the entries in Figure 1 accordingly. Green and red colours were
used to identify the 20% of countries with the highest and the
lowest, respectively, survival estimates for each type of cancer. We
then sorted the countries in each of the two analyses by their
scores of greens and reds across the cancer types. Not all the
cancer-specific estimates were available for all the countries, and
we constructed the analysis of the quintiles and the subsequent
sorting of the countries, so as to be independent of the actual
number of cancer types reported from each country.
Not all countries in Europe have complete coverage of cancer
registration but, regardless of this, we summarised results under
the heading of the name of each country. The EUROCARE-4*Correspondence: Professor H Møller; E-mail: henrik.moller@kcl.ac.uk
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publication includes an analysis of the variation between cancer
registries within countries (Sant et al, 2009). It is relevant to note
that the United Kingdom and the Netherlands have little variability
between their regional cancer registries. In France, Switzerland and
Italy, where the population coverage of cancer registration is 11%,
27% and 25%, respectively, there is a higher degree of variability
between their regional cancer registries. In consequence, the true
survival statistics for the latter national populations are not well
known at present, and the currently available estimates could
change substantially if cancer registration was extended to the
entire national populations.
RESULTS
Figure 1 summarises the results for the age-standardised 1-year
relative survival (upper panel) and for the 5|1-year conditional
relative survival (lower panel). The analysis of 1-year survival had
good discriminatory power, and visibly separated a group of
countries with consistently high survival estimates (Switzerland,
France, Sweden, Belgium and Italy) and another group of countries
with lower estimates (Poland, Czech Republic, Ireland, Denmark
and United Kingdom-Northern Ireland). The consistency of the
pattern across cancer types was considerable, with only a few
‘outlying’ red cells in the upper part and only a few green cells in
the lower part. Where such ‘exceptions’ occurred, they were most
often in rare cancers, where the estimates are inherently less
precise (e.g. soft tissue cancer in Switzerland and nasal cancer in
Poland). The four UK countries were in the lower part of Figure 1.
The analysis of 5|1-year conditional survival (i.e. cancer survival
in the 4-year interval from 1 year after the cancer diagnosis to 5
years after diagnosis) was much less discriminatory (Figure 1;
lower panel). The countries with the highest or the lowest overall
rank also included some cancer types from the opposite end of the
survival spectrum. For example, Austria had relatively low survival
for cancer of the tongue and for four other cancer types, and
Slovenia had relatively high survival from non-Hodgkin lymphoma
and for five other types of cancer. The four UK countries were now
higher and England was ranked above the European average.
DISCUSSION
The main question that this summary view of the data provokes
concerns the origins of the consistent pattern observed in the
short-term survival estimates.
An important feature of this analysis is that each type of cancer
carries the same weight in the analysis, regardless of its level of
incidence and its case fatality. One alternative analysis of the data
would be to look at the aggregate survival from all types of cancer
combined. However, such an analysis would be heavily influenced
by the most common cancers (e.g. colorectal, lung, breast and
prostate cancer) and it would miss details contributed by the less
common cancers. The inclusion of very rare cancers with unstable
survival estimates introduces random error into the current
analysis, which could obscure a genuine pattern. On the other
hand, their inclusion is not likely to spuriously generate any
artificial pattern or structure in the data. Regardless, it may be
useful to check any observation of high or low survival from the
detailed analysis with an analysis of all cancers combined.
The 1-year and the 5|1-year survival estimates are statistically
independent: the value of one is not constrained by the value of the
other. The two estimates represent short-term and medium-term
mortality events, and they combine multiplicatively to give the
conventional 5-year cumulative survival proportion. However,
when it comes to interpretation, there is a sequential dependence
between 1-year survival and 5|1-year conditional survival. Surviv-
ing in the short term is a precondition for possibly enjoying the
benefits of medium- and long-term survival and cure.
Models for understanding and describing any observed differ-
ences in cancer survival include at least three (not mutually
exclusive) general mechanisms. Variation in cancer survival can be
due to differences in the effectiveness of therapy and care for can-
cer patients (other things being equal); it can be due to differences
in patient and disease characteristics, such as stage of disease or
co-morbidity (other things being equal); and it can be indepen-
dently brought about by systematic differences in the available
data on cancer incidence and on deaths among cancer patients in
the compared populations. It would be misguided to have an
a priori preference for (or aversion to) any of these mechanisms.
Countries with very high cancer survival
The analysis identifies a number of countries where cancer
survival is consistently high in many types of cancer in 1-year
survival, in 5|1-year survival or in both: Switzerland, France,
Sweden, Belgium, Italy, the Netherlands, Austria, Germany and
Malta. Most of these countries have either partial coverage of
cancer registration (ranging from 1% in Germany to 58% in
Belgium) or small population size (Malta). Sweden may be seen as
an example of the realisation of excellent survival outcomes
through high-quality cancer care services and a cancer information
and intelligence system that provides reliable cancer survival
estimates. Sweden is a prosperous welfare state with publicly
funded, well-organised and accessible health services. The
population has a high level of education. Sweden has a system of
central population registration and uses universal, unique person
identifiers to resolve person-level identities and record linkages in
its cancer registration and death certification processes. There is,
however, one known feature of the Swedish cancer registration
system that biases the survival estimates upwards. Cancer
registration in Sweden does not use death certification as a means
of primary case ascertainment, and the registry, therefore, misses a
small proportion of fatal cancers that most other cancer registries
would detect and register as ‘death-certificate-initiated’ cases
(Parkin and Bray, 2009).
Another scenario where artificially high survival estimates occur
is when the cancer registry has incomplete ascertainment of the
deaths that occur among the persons on the register. In 2003, we
did a similar visual summary analysis (unpublished; available from
the authors) of the EUROCARE-3 data (Sant et al, 2003). Spain
seemed to have very consistent, high cancer survival. In 2004,
Carmen Martinez-Garcia from the cancer registry in Granada
reported (oral presentation, Ragusa, September 2004) that the
ascertainment of death events in some cancer registries in Spain
had been inadequate. The erroneous data are included in the
publication by Sant et al (2003) and no formal correction has been
indexed in MEDLINE. The situation seems to have been corrected
in EUROCARE-4 and Spain is no longer in the top bracket of
cancer survival.
The example of Spain may apply elsewhere, however, because in
many continental European countries, there are legislative and
administrative barriers, which prevent cancer registries from
gaining access to information about deaths. In this analysis, for
example, the consistently high survival estimates in Belgium and
the Netherlands may raise suspicion of incomplete ascertainment
of deaths. In Belgium, in particular, there are surprisingly high
5-year survival estimates for a number of generally fatal types of
cancer: oesophagus, pancreas, gallbladder and biliary tract, lung
and acute myeloid leukaemia (Sant et al, 2009). Clinical excellence
or a favourable stage distribution is certainly not ruled out in
Belgium or elsewhere, but would be unlikely to apply simulta-
neously to all the most fatal types of cancer (Carpelan-Holmstrom
et al, 2005).
Austria has very high survival estimates in the 5|1-year analysis,
but not in the 1-year estimates. In the 2003 analysis of
EUROCARE-3 data, Austria had the highest survival estimates of
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all countries in Europe. The country was then represented by a
single regional cancer registry comprising only 8% of the
population, but in the current analysis, the new national cancer
registry was used. How can a population plausibly have excellent
cancer survival in the medium term, but average cancer survival in
the short term? Clinical excellence or favourable stage distribution
that acted in the medium term should act in the short term as well.
One hypothesis, motivated by these data, may be that the
completeness of ascertainment of deaths has changed with the
introduction of the national cancer registration system.
France has a distinct pattern, which is the opposite of that in
Austria: cancer survival in the short term is remarkably high, but
after the first year survival changes to a very low level. Could it be
that the French cancer registries are incomplete in the primary
ascertainment of late stage cases, such as those cases that other
registries may identify through the use of death certificates? The
pattern is strange and not easy to attribute to a plausible clinical or
behavioural scenario.
We do not wish to hypothesise about the cancer registration
circumstances in each European country, but colleagues who are
familiar with the details of cancer registration in Switzerland, Italy,
Germany and other countries may perhaps have clues regarding
the specific situations in these countries and the possible roles of
cancer services, stage of disease and cancer registration processes
in the survival estimates. There may be important lessons to learn
from these countries, but we do not yet know what they are.
Countries with very low cancer survival
Consistently low cancer survival is evident in the former
communist east and central European countries: Poland, the
Czech Republic and Slovenia. This is most likely due to a shortage
of infrastructure and lack of financial resources for cancer care in
these countries. The low survival from testicular cancer, for
example, points to a shortage of platinum-based chemotherapeutic
agents.
Denmark and Northern Ireland also seem to have low cancer
survival in both periods of follow-up. The situation in Denmark with
respect to cancer registration, ascertainment of deaths and access to
tax-financed cancer care services is very similar to that in Sweden, yet
the two countries are at opposite ends of the spectrum of cancer
survival. The low cancer survival in Denmark has been confirmed in
several detailed studies, but the reasons are not entirely clear
(Engeland et al, 1998; Jensen et al, 2004; Mainz et al, 2009).
Northern Ireland is a small country and represents the lower end
of the spectrum of estimates from the UK countries. Ireland also
has consistent very low 1-year survival, but has very good 5|1-year
conditional survival. In the aggregate 5-year survival analysis, both
Northern Ireland and Ireland have survival within the range of the
other UK countries (Sant et al, 2009).
UK perspective: who should we compare ourselves with?
It is well established that cancer survival in the United Kingdom is
lower than we would expect from comparable European countries, but
there is some contention about the most appropriate comparison.
Clearly, there is the risk that some of the highest estimates are
unrealistically high (e.g. Spain, Belgium, as discussed above) even if we
are uncertain about the causes. For a comparison with the European
average, see Thomson and Forman, 2009.
A rational comparison could select countries with data-quality,
prosperity and healthcare system that are similar to the situation
in the United Kingdom. The Nordic and the UK countries have
many similar features: cancer registration covers the entire
population in each country and is mostly of a high degree of
completeness by international standards; the registries have access
to death certification data and robust means of linking death
information to the cancer registration record; the countries have a
tax-financed healthcare system and cancer care services are free
and accessible to the entire population. We may choose to omit
Iceland from the comparison because of its very small population
size, and we remain aware that the estimates from Sweden are too
high because of the different policy regarding the use of death
certificates in the cancer registration process.
There are two potentially strong biases that still might apply: the
effect of the routine exclusion of death-certificate-only registra-
tions from the survival analysis and the effect of the known
incompleteness of at least some UK cancer registries (Bullard et al,
2000). A detailed analysis of data from the Thames Cancer Registry
and the Finnish Cancer Registry showed that for a comparison of
the UK and Nordic countries, the two effects act in opposite
directions (Robinson et al, 2007).
Where, then, does this leave the assessment of cancer survival in
the United Kingdom? Too low, unfortunately. In this analysis, all
four UK countries have lower survival than Norway, Finland and
Sweden, both in the 1-year and the 5|1-year analysis. There is not
much difference between the two analyses: in both, the UK
countries are in the lower half and Norway, Sweden and Finland
are in the upper half of Figure 1.
If we look at the alternative analysis of the survival from all
cancers combined (Sant et al, 2009), a clear difference between the
1-year and the 5|1-year conditional analysis appears. This analysis
suggests that the UK deficit in survival compared with the Nordic
countries is different in the two periods of follow-up. In the first
year, the weighted 1-year survival is 63.8% in the United Kingdom
and 74.6% in Norway, Sweden and Finland, a difference of 10.8
percentage points. In the 5|1-year analysis, the difference is
smaller: 72.1% in the United Kingdom vs 75.7% in the three Nordic
countries, a difference of 3.6 percentage points.
In otherwise comparable populations, a pronounced difference
in 1-year survival is most likely to be due to variation in a strong
prognostic factor, which exerts its effect in the short term. A likely
explanation for the short-term survival deficit in the United
Kingdom compared with the Nordic countries is a less favourable
stage distribution in the United Kingdom, but the present
superficial analysis does not exclude possible functions for other
factors relating to the organisation and quality of cancer care
services.
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